Crispr Therapeutics AG's total assets for Q2 2026 were $2.65B, a decrease of -2.75% from the previous quarter. MX:CRSPN total liabilities were $904.22M for the fiscal quarter, a -0.77% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.